Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| New York Genome Center | RCV001839117 | SCV002099032 | uncertain significance | Developmental and epileptic encephalopathy, 78 | 2021-03-05 | criteria provided, single submitter | clinical testing | The inherited c.764T>C ( p.Ile255Thr) variant identified in the GABRA2 gene substitutes a well conserved Isoleucine for Threonine at amino acid 255/452 (exon 8/10). This variant is absent from gnomAD(v3.1) suggesting it is not a common benign variant in the populations represented in that database. In silico algorithms predict this variant to be Damaging (SIFT; score: 0.00) and Pathogenic (REVEL; score:0.927) to the function of the canonical transcript. This variant is absent from ClinVar and to our current knowledge has not been reported in affected individuals in the literature. The p.Ile255 residue is within the first helical transmembrane domain of GABRA2 (UniProtKB:P47869), and to date all pathogenic variants identified have been in one of the helical transmembrane domains within this region (for Review, see [PMID:32347641, 31032849]). The inherited c.764T>C (p.Ile255Thr) variant identified in the GABRA2 gene is reported as a Variant of Uncertain Significance. |
| Labcorp Genetics |
RCV002542821 | SCV003511310 | likely benign | not provided | 2024-01-22 | criteria provided, single submitter | clinical testing |